White Paper

Role Of Cell Based Potency Assay In Functional Characterization Of Therapeutic Monoclonal Antibodies (mAbs)

By Agata Burzawa and Pamela Hamill, Ph.D.


Characterization of an originator monoclonal antibody (mAb), or comparability study between originator mAb and biosimilar candidate mAb, are challenging due to the highly complex and variable structure of monoclonal antibodies. The heterogeneity that can arise in quality attributes, including structural alterations, oxidation, deamination or glycosylation, can impact the potency and the efficacy of the final product. Moreover, mAbs have multiple biological functions associated with both the specific antigen binding (Fab) region and interaction with C1q and Fc receptors via the Fc region of the antibody. For this reason, the characterization of therapeutic monoclonal antibodies should include a wide range of analytical techniques; as well as binding and cell-based potency assays in order to reflect the main mechanism of action and effector function of the mAb of interest.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development